Dark

Check out our Dark Pool Levels

CLABF
CORE ONE LABS INC
stock OTC

EOD

Aug 3, 2026

0.000001USD0.000%(0.000000)6,062

Pre-market

0.00USD-100.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 26, 2022

02:55AM EST Core One Labs Akome Biotech Signs Research GlobeNewswire Inc

Jan 21, 2022

04:22PM EST Core One Labs Announces Successful Proof of Concept and Files GlobeNewswire Inc

Jan 18, 2022

01:00PM EST Core One Labs Special Investor Webcast Rescheduled to Friday, GlobeNewswire Inc

Jan 15, 2022

07:25PM EST Core One Labs to Host Special Investor Webcast on Tuesday, January GlobeNewswire Inc

Jan 8, 2022

06:55PM EST Core One Labs Now Also Working to Biosynthesize DMT and Receives GlobeNewswire Inc

Jan 5, 2022

07:29PM EST Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the Company or Core One) applauds Health Canada for its recent amendment to the Special Access Programme (SAP), which will now allow physicians to request patient access to psychedelic treatments, including psilocybin-assisted therapy. GlobeNewswire Inc

Dec 27, 2021

01:12PM EST Psychedelics Company Core One Labs Dives Into Functional Mushrooms With New $3M Acquisition Benzinga

Dec 23, 2021

05:00PM EST Core One Labs Acquires New Path Laboratories GlobeNewswire Inc

Oct 18, 2021

01:37PM EDT Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation Benzinga

Oct 16, 2021

09:00PM EDT Core One Labs Applauds the City of Seattle in Their Efforts to GlobeNewswire Inc

Oct 13, 2021

04:25PM EDT There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are Benzinga

Aug 23, 2021

09:01AM EDT Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up Benzinga

Jul 17, 2021

07:00PM EDT Core One Labs to Present on its Proprietary Biosynthetic GlobeNewswire Inc

Jul 16, 2021

03:00AM EDT Core One Labs Announces Details of Consolidation to Meet Nasdaq GlobeNewswire Inc

Jun 21, 2021

09:15AM EDT Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the Company) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (Akome) has commenced the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic strokes. GlobeNewswire Inc

Jun 18, 2021

03:00AM EDT Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the Company) is pleased to announce it has retained Smart & Biggar LLP (Smart and Biggar) to handle all IP filings for Akome Biotech Ltd. (Akome) and Vocan Biotechnologies Inc. (Vocan). GlobeNewswire Inc

Jun 16, 2021

03:00AM EDT Core One Labs Plans Share Consolidation in Preparation of Listing GlobeNewswire Inc

Jun 14, 2021

09:15AM EDT REPEAT - Core One Labs Biosynthesized Psilocybin GlobeNewswire Inc

Jun 12, 2021

06:40PM EDT Core One Labs Biosynthesized Psilocybin GlobeNewswire Inc

May 10, 2021

10:49AM EDT Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M Benzinga

May 6, 2021

09:00AM EDT Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the Company or Core One) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (Akome) has commenced the development of its next-generation patent pending psychedelic drug formulation for the treatment of Alzheimers Disease (Alzheimers). GlobeNewswire Inc

May 5, 2021

09:00AM EDT Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the Company or Core One) is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. (Akome), as Chief Medical Officer of the Company. Dr. Ferro will lead the Company through clinical trials and commercialization of its psychedelic products. GlobeNewswire Inc

May 4, 2021

09:00AM EDT REPEAT - Core One Labs Completes Milestone Acquisition of Akome GlobeNewswire Inc

03:10AM EDT Core One Labs Completes Milestone Acquisition of Akome Biotech GlobeNewswire Inc

Apr 29, 2021

09:00AM EDT REPEAT -- Core One Labs Reaches Definitive Agreement to Acquire GlobeNewswire Inc

04:00AM EDT Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech GlobeNewswire Inc

Apr 28, 2021

09:00AM EDT REPEAT -- Core One Labs to Explore Joint Venture with Lobe GlobeNewswire Inc

03:30AM EDT Core One Labs to Explore Joint Venture with Lobe Sciences for the GlobeNewswire Inc

Apr 26, 2021

09:00AM EDT Repeat: Core One Labs Vocan Biotechnologies Enters into GlobeNewswire Inc

08:03AM EDT Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading Benzinga

07:58AM EDT Psyched: MindMed and Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Gets Back To Trading Benzinga

07:07AM EDT Emerging Markets Report: The Rich Get Richer GlobeNewswire Inc

Apr 24, 2021

06:00PM EDT Core One Labs Vocan Biotechnologies Enters into Collaborative GlobeNewswire Inc

Apr 21, 2021

09:00AM EDT REPEAT: Core One Labs Vocan Initiates GlobeNewswire Inc

04:05AM EDT Core One Labs Vocan Initiates Engineering and GlobeNewswire Inc

Apr 14, 2021

11:29AM EDT Emerging Markets Report: A Moment for the Mushroom GlobeNewswire Inc

Apr 12, 2021

08:12AM EDT Psyched: Entheon Launches Psychedelics Genetic Test, Mydecine Unveils Psychedelic Drug Candidates, California Bill Passes Senate Committee Benzinga

Apr 6, 2021

11:39AM EDT Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree Benzinga

Mar 22, 2021

09:00AM EDT Repeat: Core One Labs Files Application to List its Common Shares GlobeNewswire Inc

Mar 20, 2021

04:00PM EDT Core One Labs Files Application to List its Common Shares on NASDAQ GlobeNewswire Inc

Jan 1, 2021

10:49AM EST Psyched: The First Psychedelics ETF, Beckley Raises $19M, 3 Companies Go Public Benzinga

Share